Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012
Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources
WALTHAM, Mass., Jan. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues,...
Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis
However, Pharmacy Directors Disagree About Formulary Inclusion for Key
Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources
WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the
Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis
The first Phase III study involving the use of Actemra
in the treatment of rheumatoid arthritis has revealed that it is superior to conventional treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs to inhibit // joint destruction. It has also been found to provide symptomatic...
Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
...he established TNFs (Enbrel, Humira, and Remicade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that actemra
would be most likely to replace BMS's Orencia in their practices.
LaunchTrends (TM) measure launch effectiveness of new products from FDA appr...
ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress
...f Phase III clinical studies highlight benefits of actemra
as a treatment for rheumatoid arthritis -
About ACTEMRA(R) (tocilizumab)
is the first humanized interleukin-6 (IL-6) recept...nd have reported meeting their primary endpoints. actemra
is currently under review by the FDA in the United...
FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis
are hopeful that the FDA will approve actemra
for the treatment of RA and
provide a new option t...nt program was designed to
evaluate the effects of actemra
on signs and symptoms of RA, physical
therapy, and one monotherapy study comparing actemra
to methotrexate, a
current standard of care, was a...
Roches Arthritis Drug Successful in III Stage Trail
... Roche Holding AG says that arthritis drug actemra
has proved successful in a phase III clinical study. actemra
helps relieve symptoms of rheumatoid arthritis in...eeks with 498 patients with difficult-to-treat RA. actemra
was given in combination with a standard treatment...
New Drug for Rheumatoid Arthritis Looks Promising.
...y. Drug maker Roche Holding AG will file the drug actemra
for regulatory approval in Europe and the U.S. lat...ntrolled by Roche. Roche owns the rights to market actemra
Two other drugs rituxima...d to disability.
The new treatment option actemra
in combination with traditional drugs achieved a s...
Actemra in Medical Technology
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
- By targeting interleukin-6 receptors, ACTEMRA
provides significant benefits for patients when compared with existing therapies -
NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid
arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced
significant and rapid re...
Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
... - Additional data reinforce long-term efficacy of actemra
across a broad range of rheumatoid arthritis patie...ng with additional studies that support the use of actemra
as a long-term treatment option for patients with ...30 percent and 47 percent of patients treated with actemra
4 mg/kg and 8 mg/kg, respectively, compared with 8...
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
... - Fifth International Phase III actemra
Study Meets its Primary Endpoints -
NUTLEY, N...RA). The study also showed that patients receiving actemra
experienced improved physical function, as measure...fth international Phase III study in the extensive actemra
clinical development program to successfully meet ...
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
...health care professionals prescribe and administer actemra
correctly, and that patients understand the potent...animal model data, beyond what was included in the actemra
BLA. Roche is performing the requested pre-clinica...s to confirm the published literature showing that actemra
does not affect peri- and post-natal development, ...
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
...mproved physical function in patients
treated with actemra
NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year... "The LITHE study demonstrated that treatment with actemra
structural joint damage, which is a majo...erosion and joint space
narrowing, was lower among actemra
(8 mg/kg and 4 mg/kg) plus
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
...ions, along with 13 other
abstracts which evaluate actemra
in patients with moderately to severely
active RA,...studies further support the
efficacy and safety of actemra
as a potential new treatment option for
managing t... The AMBITION study, which examined the effects of actemra
(8 mg/kg) as
monotherapy, showed that 70 percent o...
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
... - Phase III monotherapy study shows actemra
is first and only biologic to
demonstrate statis... showed that significantly more
patients receiving actemra
achieved a 20 percent improvement in their signs
a...r at week 24. In addition, nearly one-third of
patients from both studies reached disease remissi...
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
...e LITHE study is the
fifth international Phase III actemra
trial to successfully meet its
primary endpoints i...that a greater proportion of patients
treated with actemra
(4 mg/kg or 8 mg/kg) plus methotrexate versus plac...ent of the
patients were from the United States.
was generally well tolerated; the most common adve...
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
...evere rheumatoid arthritis (RA).
"The filing for actemra
represents a significant milestone for Roche,
and ...ombie, President and CEO, Hoffmann-La Roche
is the first humanized interleukin-6 (IL-6) recept...international Phase III studies which demonstrated actemra
or in combination with disease modi...
Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
...toms achieved with the unique inhibiting action of actemra
that specifically targets interleukin-...the findings of this new TOWARD data which
plus DMARDs demonstrates significant improvement i...rom both studies
further establish the efficacy of actemra
and confirm that inhibiting
interleukin-6 (IL-6) r...
Actemra in Biological News
Actemra in Biological Technology